



Astec LifeSciences Ltd.

Dated: 28<sup>th</sup> May, 2012

To,  
**The Department of Corporate Services**  
**National Stock Exchange Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra, Mumbai-400051

Ref: "ASTEC"

Sub: Outcome of Audit Committee Meeting.

Dear Sir,

This is to inform you that the Members of Audit Committee at their meeting held on Monday 28<sup>th</sup> May, 2012 has:

- 4) Recommended appointment of Mr. Mandar K. Patil as a member of Audit Committee for the approval of Board of Directors with effect from 27<sup>th</sup> May, 2012.

The Audit Committee will now be comprised of:


Sr. No	Name of Member	Position
1	Mr. Sitendu Sharma	Chairman-Non-Executive & Independent Director
2	Mr. Laxmikant Kabra	Non-Executive & Non-Independent Director
3	Mr. Zakir Mohammed	Non-Executive & Independent Director
4	Mandar K. Patil	Non-Executive & Independent Director

Please take the same on your records.

Thanking you,

Yours Sincerely,

**FOR ASTEC LIFESCIENCES LIMITED**

  
**Vikas R. Chomal**  
Company Secretary & Compliance Officer



Head Office  
Elite Square, 7th Floor,  
274, Perin Nariman Street,  
Fort, Mumbai - 400001 India  
Phone +91-22- 2261 8212/ 2261 8504  
Fax +91-22- 2261 8289  
E-mail ah@astecsl.com  
Website www.astecsl.com



Astec LifeSciences Ltd.

**Dated:** 28<sup>th</sup> May, 2012

To,  
**The Department of Corporate Services**  
**National Stock Exchange Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra, Mumbai-400051

**Ref:** "ASTEC"

**Sub:** Outcome of Board Meeting.

Dear Sir,

This is to inform you that the Board of Directors at their meeting held on Monday 28<sup>th</sup> May, 2012 has:

- 1) Approved the Audited Financial Results (both Standalone & Consolidated) for the year ended 31<sup>st</sup> March, 2012.
- 2) Recommended a dividend of fifty paise per share (i.e. 5% on the face value of Rs.10/- each) for the approval of the Shareholders at the ensuing Annual General Meeting: *MEGA*
- 3) Appointed Mr. Mandar K. Patil as Non-Executive & Independent Director on the Board of the Company and member of Audit Committee with effect from 27<sup>th</sup> May, 2012.

Please take the same on your records.

**Thanking you,**

**Yours Sincerely,**

**FOR ASTEC LIFESCIENCES LIMITED**

*Chomal*  
Vikas R. Chomal

**Company Secretary & Compliance Officer**



**Encl:** as above



Head Office  
Elite Square, 7th Floor,  
274, Perin Nariman Street,  
Fort, Mumbai - 400001, India  
Phone: +91-22- 2261 8212/ 2261 8504  
Fax +91-22- 2261 8289  
E-mail: ah@astecis.com  
Website: www.astecis.com


**ASTEC LIFESCIENCES LTD**

Regd. Office : 7th Floor, Elite Square, 274, Perin Nariman Street, Fort, Mumbai- 400001.

**Audited Financial Results for the quarter/year ended 31st March, 2012**

PART I						
STANDALONE						
Rs. In Lacs ( Except for per share data )						
Sr. No	Particulars	Quarter Ended			Year to date figures for current period ended	Year to date figures for previous period ended
		31-03-2012	31-12-2011	31-03-2011	31-03-2012	31-03-2011
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>1</b>	<b>Income from Operations</b>					
a)	Net Sales / Income from operations ( Net of Excise Duty)	2,563.49	2,822.61	2,335.54	11,084.06	11,112.40
b)	Other Operating Income	32.89	31.66	(5.95)	74.01	81.65
	<b>Total Income from Operations (net)</b>	<b>2,596.38</b>	<b>2,854.27</b>	<b>2,329.59</b>	<b>11,158.07</b>	<b>11,194.05</b>
<b>2</b>	<b>Expenses</b>					
a)	Cost of materials consumed	2,101.90	2,688.86	1,271.45	8,479.21	7,278.84
b)	Purchase of stock in trade	-	-	259.60	696.99	1,845.38
c)	Changes in inventories of finished goods and work in progress	(142.14)	(657.20)	460.21	(823.86)	(462.52)
d)	Employee benefits expenses	94.58	165.38	102.41	474.79	392.65
e)	Depreciation and amortisation expenses	224.24	214.47	194.64	847.54	577.32
f)	Other expenditure	106.59	143.80	105.13	441.73	465.38
	<b>Total Expenses</b>	<b>2,385.18</b>	<b>2,555.32</b>	<b>2,393.44</b>	<b>10,116.39</b>	<b>10,097.05</b>
<b>3</b>	<b>Profit/ (Loss) from operations before other income, Finance Cost and Exceptional Items (1-2)</b>	<b>211.20</b>	<b>298.95</b>	<b>(63.85)</b>	<b>1,041.67</b>	<b>1,097.00</b>
4	Other Income	7.01	8.64	9.30	27.88	21.26
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	218.21	307.59	(54.55)	1,069.55	1,118.26
6	Finance Costs	135.15	162.81	104.86	534.29	403.54
6A	Foreign Exchange Fluctuation ( Profit ) / Loss	61.77	73.34	9.33	176.83	0.68
7	Profit after finance costs but before Exceptional Items (5-6-6A)	21.28	71.44	(168.74)	358.43	714.04
8	Exceptional Items (Includes adjustment relating to previous year)	10.64	2.01	(9.69)	14.11	(2.18)
9	Profit / (Loss) from ordinary activities before tax (7-8)	10.64	69.43	(159.05)	344.32	716.22
10	Tax Expense	35.78	13.59	31.44	102.52	207.79
11	Net Profit Profit / (Loss) from ordinary activities after tax (9-10)	(25.14)	55.84	(190.49)	241.80	508.43
12	Extra ordinary Items	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 - 12)	(25.14)	55.84	(190.49)	241.80	508.43
14	Share of Profit / (Loss) of associates	-	-	-	-	-
15	Minority Interest	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (Loss) of associates (13-14-15)	(25.14)	55.84	(190.49)	241.80	508.43
17	Paid-up equity share capital (Face Value Rs.10/-)	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	8,147.35	8,003.93
19	Earnings per share - Basic & Diluted	(0.15)	0.33	(1.13)	1.43	3.00
<b>PART II</b>						
<b>Select information for the year ended 31st March, 2012</b>						
<b>A PARTICULARS OF SHAREHOLDING</b>						
1	Public shareholding					
	- No of shares	74,97,150	75,00,150	75,00,150	74,97,150	75,00,150
	- Percentage of shareholding	44.29%	44.30%	44.30%	44.29%	44.30%
2	Promoters and promoter group shareholding					
a)	Pledged / Encumbered					
	- No of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	0.00%	0.00%	0.00%	0.00%	0.00%
	- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%
b)	Non-encumbered					
	- No of shares	94,31,980	94,28,980	94,28,980	94,31,980	94,28,980
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	55.71%	55.70%	55.70%	55.71%	55.70%
<b>PARTICULARS</b>		3 Months ended 31/03/2012				
<b>B INVESTOR COMPLAINTS</b>						
	Pending at the beginning of the quarter	Nil				
	Received during the quarter	Nil				
	Disposed of during the quarter	Nil				
	Remaining unresolved at the end of the quarter	Nil				

- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on May 28, 2012.
- The company has only one reportable segment i.e. Agrochemicals & Pharma Intermediates.
- The Board of Directors has recommended a dividend of 5% on the share capital of the company i.e. 50 paise per share of Rs. 10/- each.
- Figures of the previous period have been regrouped/rearranged, wherever necessary.



B

Statement of Assets and Liabilities (Consolidated)		Rs. In Lacs	
		31-03-2012	31-03-2011
Particulars		(Audited)	(Audited)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	Shareholders' Funds :		
	(a) Share Capital	1,692.91	1,705.99
	(b) Reserves and Surplus	8,023.59	7,963.48
	(c) Money Received against Share Warrants	136.00	-
	<b>Sub Total - Shareholders' Funds</b>	<b>9,852.51</b>	<b>9,669.47</b>
2	Minority Interest	18.12	22.81
3	<b>Non-Current Liabilities</b>		
	(a) Long Term Borrowings	1,179.33	237.06
	(b) Deferred Tax Liabilities (net)	278.92	243.92
	(c) Other Longs Term Liabilities	2,182.92	342.51
	(d) Long Term Provisions	34.07	78.22
	<b>Sub total - Non Current Liabilities</b>	<b>3,675.24</b>	<b>901.71</b>
4	<b>Current Liabilities</b>		
	(a) Short Term Borrowings	5,915.04	3,887.59
	(b) Trade Payables	3,098.05	2,301.69
	(c) Other Current Liabilities	489.21	504.20
	(d) Short Term Provisions	145.00	100.17
	<b>Sub total - Current Liabilities</b>	<b>9,647.31</b>	<b>6,793.65</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>23,193.18</b>	<b>17,387.64</b>
<b>B</b>	<b>ASSETS :</b>		
1	<b>Non Current Assets</b>		
	(a) Fixed Assets	11,985.73	8,169.27
	(b) Goodwill on consolidation	-	-
	(c) Non Current Investments	1.18	5.95
	(d) Deferred tax assets (net)	49.64	-
	(e) Long term loans and advances	324.99	117.68
	(f) Other non current assets	-	5.45
	<b>Sub total - non current assets</b>	<b>12,361.54</b>	<b>8,298.35</b>
2	<b>Current Assets</b>		
	(a) Current Investments	1,180.82	794.72
	(b) Inventories	5,038.47	3,684.71
	(c) Trade Receivables	3,187.40	3,425.59
	(d) Cash and cash equivalents	410.64	309.98
	(e) Short term loans and advances	1,014.32	874.29
	(f) Other current assets	-	-
	<b>Sub total - current assets</b>	<b>10,831.65</b>	<b>9,089.29</b>
	<b>TOTAL ASSETS</b>	<b>23,193.18</b>	<b>17,387.64</b>

For Astec LifeSciences Limited

(Ashok V Hiremath)  
Chairman & Managing Director  
Mumbai, May 28, 2012




**ASTEC LIFESCIENCES LTD**

Regd. Office : 7th Floor, Elite Square, 274, Perin Nariman Street, Fort, Mumbai- 400001.

**Audited Financial Results for the quarter/year ended 31st March, 2012**

PART I		CONSOLIDATED				
		Rs. In Lacs ( Except for per share data )				
Sr. No	Particulars	Quarter Ended			Year to date figures for current period ended	Year to date figures for previous period ended
		31-03-2012	31-12-2011	31-03-2011	31-03-2012	31-03-2011
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>1</b>	<b>Income from Operations</b>					
a)	Net Sales / Income from operations ( Net of Excise Duty)	2,540.42	2,922.13	2,177.44	11,284.48	10,962.40
b)	Other Operating Income	17.72	16.70	(5.84)	32.58	81.76
	<b>Total Income from Operations (net)</b>	<b>2,558.14</b>	<b>2,938.83</b>	<b>2,171.59</b>	<b>11,317.06</b>	<b>11,044.16</b>
<b>2</b>	<b>Expenses</b>					
a)	Cost of materials consumed	1,934.81	2,956.87	1,260.65	8,923.94	7,278.84
b)	Purchase of stock in trade	-	-	259.60	696.99	1,845.38
c)	Changes in inventories of finished goods and work in progress	19.75	(855.61)	310.29	(1,174.91)	(612.44)
d)	Employee benefits expenses	130.19	193.76	111.35	557.53	401.59
e)	Depreciation and amortisation expenses	225.49	215.72	196.46	863.79	583.00
f)	Other expenditure	136.96	169.59	113.29	540.41	466.44
	<b>Total Expenses</b>	<b>2,447.21</b>	<b>2,680.34</b>	<b>2,251.64</b>	<b>10,407.74</b>	<b>9,962.81</b>
<b>3</b>	<b>Profit/ (Loss) from operations before other income, Finance Cost and Exceptional Items (1-2)</b>	<b>110.93</b>	<b>258.49</b>	<b>(80.05)</b>	<b>909.31</b>	<b>1,081.34</b>
4	Other income	7.01	8.64	9.30	28.73	21.26
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	117.94	267.13	(70.75)	938.04	1,102.60
6	Finance Costs	147.44	175.41	106.95	565.92	405.63
6A	Foreign Exchange Fluctuation ( Profit ) / Loss	61.77	73.34	9.33	176.83	0.68
7	Profit after finance costs but before Exceptional Items (5-6-6A)	(91.28)	18.38	(187.03)	195.29	696.29
8	Exceptional Items (Includes adjustment relating to previous year)	10.64	2.01	(9.69)	14.11	(2.18)
9	Profit / (Loss) from ordinary activities before tax (7-8)	(101.92)	16.37	(177.34)	181.18	698.47
10	Tax Expense	(14.64)	13.79	32.06	53.79	208.58
11	Net Profit Profit / (Loss) from ordinary activities after tax (9-10)	(87.28)	2.59	(209.40)	127.39	489.89
12	Extra ordinary Items	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 - 12)	(87.28)	2.59	(209.40)	127.39	489.89
14	Share of Profit / (Loss) of associates	-	-	-	-	-
15	Minority Interest	0.04	0.15	(0.11)	(9.17)	0.05
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (Loss) of associates (13-14-15)	(87.32)	2.44	(209.29)	136.56	489.84
17	Paid-up equity share capital (Face Value Rs.10/-)	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	8,023.59	7,986.63
19	Earnings per share - Basic & Diluted	(0.52)	0.01	(1.24)	0.81	2.89

**PART II**
**Select information for the year ended 31st March, 2012**
**A PARTICULARS OF SHAREHOLDING**

<b>1</b>	<b>Public shareholding</b>					
	- No of shares	74,97,150	75,00,150	75,00,150	74,97,150	75,00,150
	- Percentage of shareholding	44.29%	44.30%	44.30%	44.29%	44.30%
<b>2</b>	<b>Promoters and promoter group shareholding</b>					
a)	<b>Pledged / Encumbered</b>					
	- No of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	0.00%	0.00%	0.00%	0.00%	0.00%
	- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%
b)	<b>Non-encumbered</b>					
	- No of shares	94,31,980	94,28,980	94,28,980	94,31,980	94,28,980
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	55.71%	55.70%	55.70%	55.71%	55.70%

**PARTICULARS**

 3 Months ended  
31/03/2012

**B INVESTOR COMPLAINTS**

Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil

- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on May 28, 2012.
- The company has only one reportable segment i.e. Agrochemicals & Pharma Intermediates.
- Above Financial Results includes financials results of M/s Behram Chemicals Pvt. Ltd. (65.63% subsidiary), Astec Europe Spri (50.10% subsidiary) and Astec CropCare Pvt Ltd (100% Subsidiary of Astec).
- Astec Europe Spri became subsidiary with effect from 3rd Oct 2011.
- The Board of Directors have recommended a dividend @ 5% on the share capital of the company i.e. 50 paise per share of Rs. 10/- each.
- Figures of the previous period have been regrouped/rearranged, wherever necessary.
- Key standalone financial information of the company is given below :-

Particulars	Quarter Ended 31/03/2012	Quarter Ended 31/12/2011	Quarter Ended 31/03/2011	Year ended 31/03/2012	Year ended 31/03/2011
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Net Sales / Income from operations ( Net of Excise Duty)	2,563.49	2,822.61	2,335.54	11,084.06	11,112.40
Other Operating Income	32.89	31.66	(5.95)	74.01	81.65
Profit / (Loss) from ordinary activities before tax	10.64	69.43	(159.05)	344.32	716.22
Net Profit Profit / (Loss) from ordinary activities after tax	(25.14)	55.84	(190.49)	241.80	508.43
Earnings per share - Basic & Diluted	(0.15)	0.33	(1.13)	1.43	3.00



**ASTEC LIFESCIENCES LTD**

Regd. Office : 7th Floor, Elite Square, 274, Perin Nariman Street, Fort, Mumbai- 400001.

Statement of Assets and Liabilities (Standalone)		Rs. In Lacs	
		31-03-2012 (Audited)	31-03-2011 (Audited)
<b>A EQUITY AND LIABILITIES</b>			
<b>1 Shareholders' Funds :</b>			
(a) Share Capital	1,692.91	1,692.91	
(b) Reserves and Surplus	8,147.35	8,003.93	
(c) Money Received against Share Warrants	136.00	-	
<b>Sub Total - Shareholders' Funds</b>	<b>9,976.27</b>	<b>9,696.84</b>	
<b>2 Minority Interest</b>			
<b>3 Non-Current Liabilities</b>			
(a) Long Term Borrowings	1,108.20	212.06	
(b) Deferred Tax Liabilities (net)	275.81	241.29	
(c) Other Longs Term Liabilities	2,182.92	342.51	
(d) Long Term Provisions	34.20	78.35	
<b>Sub total - Non Current Liabilities</b>	<b>3,601.12</b>	<b>874.21</b>	
<b>4 Current Liabilities</b>			
(a) Short Term Borrowings	5,592.79	3,787.55	
(b) Trade Payables	2,951.74	2,282.87	
(c) Other Current Liabilities	457.68	485.78	
(d) Short Term Provisions	107.02	98.38	
<b>Sub total - Current Liabilities</b>	<b>9,109.22</b>	<b>6,654.58</b>	
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>22,686.61</b>	<b>17,225.63</b>	
<b>B ASSETS :</b>			
<b>1 Non-Current Assets</b>			
(a) Fixed Assets	11,919.54	8,098.08	
(b) Goodwill on consolidation	-	-	
(c) Non Current Investments	98.81	97.57	
(d) Deferred tax assets (net)	-	-	
(e) Long term loans and advances	314.87	111.46	
(f) Other non current assets	-	5.45	
<b>Sub total - non current assets</b>	<b>12,333.22</b>	<b>8,312.58</b>	
<b>2 Current Assets</b>			
(a) Current Investments	1,173.82	787.72	
(b) Inventories	4,332.30	3,534.80	
(c) Trade Receivables	3,073.02	3,425.26	
(d) Cash and cash equivalents	354.08	300.90	
(e) Short term loans and advances	1,420.17	864.38	
(f) Other current assets	-	-	
<b>Sub total - current assets</b>	<b>10,353.39</b>	<b>8,913.05</b>	
<b>TOTAL ASSETS</b>	<b>22,686.61</b>	<b>17,225.63</b>	

For Astec LifeSciences Limited

(Ashok V Hiremath)  
Chairman & Managing Director  
Mumbai, May 28, 2012

